Last reviewed · How we verify

Nordic Lymphoma Group — Portfolio Competitive Intelligence Brief

Nordic Lymphoma Group pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
R-pola-mini-CHP R-pola-mini-CHP phase 3 Monoclonal antibody + chemotherapy combination CD20 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. American Scitech International · 1 shared drug class
  2. AryoGen Pharmed Co. · 1 shared drug class
  3. Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · 1 shared drug class
  4. Cinnagen · 1 shared drug class
  5. Fondazione Italiana Linfomi - ETS · 1 shared drug class
  6. Fujian Medical University · 1 shared drug class
  7. Prof. Dr. M. Dreyling (co-chairman) · 1 shared drug class
  8. Shandong Provincial Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nordic Lymphoma Group:

Cite this brief

Drug Landscape (2026). Nordic Lymphoma Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nordic-lymphoma-group. Accessed 2026-05-16.

Related